Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Metabolic Adaptations to Chronic and Acute Exercise in Overweight Adults (ATX-Study) preliminary data (Study ST000777)

C18 NEGATIVE ION MODE (Analysis AN001228)

Metabolite	Structure	F1	F2
PG 36:3; [M-H]-@5.15	ME215204	0.36	1.64
PC 40:6; [M-Ac-H]-@6.75	ME215186	0.30	1.70
CL 78:1; [M-2H](2-)@7.48	ME215155	0.25	1.75
PG 38:5; [M-H]-@5.07	ME215206	0.25	1.75
PE 35:2; [M-H]-@6.70	ME215193	0.88	1.12
FFA(22:0)	ME215164	0.89	1.11
FFA(24:0)	ME215167	0.89	1.11
FFA(20:1)	ME215162	0.86	1.14
FFA(18:1)	ME215159	0.84	1.16
FFA(20:2)	ME215163	0.85	1.15
CL 72:8; [M-2H](2-)@8.88	ME215154	1.06	0.94
PG 36:0; [M-H]-@6.81	ME215202	1.04	0.96
CL 72:7; [M-2H](2-)@9.07	ME215153	0.96	1.04
PE 33:0; [M-H]-@7.03	ME215189	0.97	1.03
FFA(18:0)	ME215158	0.98	1.02
FFA(16:0)	ME215157	0.99	1.01
FFA(20:0)	ME215161	0.99	1.01
plasmenyl-PE 38:1; [M-H]-@8.24	ME215222	0.44	1.56
Arachidonic acid	ME215152	0.54	1.46
PE 38:6; [M-H]-@6.12	ME215198	0.53	1.47
PC 38:2; [M-Ac-H]-@7.60	ME215182	0.56	1.44
PE 40:7; [M-H]-@6.37	ME215200	0.55	1.45
PI 39:4; [M-H]-@6.08	ME215211	0.49	1.51
PC 38:6; [M-Ac-H]-@6.05	ME215185	0.48	1.52
PS 38:4; [M-H]-@5.91	ME215215	0.48	1.52
PG 36:2; [M-H]-@5.71	ME215203	0.52	1.48
PG 38:2; [M-H]-@6.07	ME215205	0.52	1.48
PS 36:2; [M-H]-@5.95	ME215214	0.51	1.49
plasmenyl-PE 38:6; [M-H]-@6.57	ME215225	0.51	1.49
plasmenyl-PE 40:4; [M-H]-@7.73	ME215226	0.51	1.49
PS 40:5; [M-H]-@6.02	ME215216	0.62	1.38
plasmenyl-PE 40:5; [M-H]-@7.39	ME215227	0.62	1.38
PE 32:1; [M-H]-@6.20	ME215188	0.62	1.38
PI 34:1; [M-H]-@5.59	ME215207	0.62	1.38
PC 35:4; [M-Ac-H]-@5.95	ME215176	0.60	1.40
CL 78:5; [M-2H](2-)@6.51	ME215156	0.61	1.39
PE 34:3; [M-H]-@6.00	ME215191	0.61	1.39
plasmenyl-PE 38:4; [M-H]-@7.21	ME215223	0.68	1.32
FFA(18:2)	ME215160	0.68	1.32
PC 32:2; [M-Ac-H]-@5.67	ME215173	0.68	1.32
plasmenyl-PE 38:5; [M-H]-@6.71	ME215224	0.69	1.31
plasmenyl-PE 32:0; [M-H]-@7.08	ME215218	0.69	1.31
PE 36:1; [M-H]-@7.44	ME215195	0.69	1.31
lysoPE 18:0; [M-H]-@2.39	ME215217	0.69	1.31
PC 32:1; [M-Ac-H]-@6.19	ME215172	0.69	1.31
PS 34:1; [M-H]-@5.75	ME215212	0.64	1.36
PE 40:3; [M-H]-@7.22	ME215199	0.64	1.36
PC 38:5; [M-Ac-H]-@6.45	ME215184	0.64	1.36
PE 32:0; [M-H]-@6.72	ME215187	0.64	1.36
PC 36:1; [M-Ac-H]-@7.47	ME215178	0.67	1.33
PS 34:2; [M-H]-@5.27	ME215213	0.67	1.33
PC 36:0; [M-Ac-H]-@8.02	ME215177	0.65	1.35
PE 36:4; [M-H]-@6.25	ME215197	0.66	1.34
FFA(24:2)	ME215169	0.66	1.34
PE 35:0; [M-H]-@7.59	ME215192	0.66	1.34
FFA(22:1)	ME215165	0.82	1.18
PE 36:0; [M-H]-@7.87	ME215194	0.81	1.19
plasmenyl-PE 34:2; [M-H]-@6.69	ME215219	0.78	1.22
plasmenyl-PE 36:2; [M-H]-@7.28	ME215220	0.78	1.22
PC 30:1; [M-Ac-H]-@5.54	ME215170	0.79	1.21
PI 38:5; [M-H]-@5.28	ME215210	0.80	1.20
PC 38:4; [M-Ac-H]-@6.87	ME215183	0.73	1.27
PI 36:4; [M-H]-@5.12	ME215208	0.73	1.27
PI 38:4; [M-H]-@5.73	ME215209	0.72	1.28
FFA(24:1)	ME215168	0.72	1.28
PE 36:3; [M-H]-@6.54	ME215196	0.72	1.28
PC 32:0; [M-Ac-H]-@6.70	ME215171	0.71	1.29
PC 36:4; [M-Ac-H]-@6.23	ME215181	0.71	1.29
FFA(22:2)	ME215166	0.77	1.23
PC 36:2; [M-Ac-H]-@6.96	ME215179	0.76	1.24
PC 36:3; [M-Ac-H]-@6.50	ME215180	0.76	1.24
PC 34:2; [M-Ac-H]-@6.31	ME215174	0.75	1.25
PG 33:0; [M-H]-@6.00	ME215201	0.75	1.25
plasmenyl-PE 36:3; [M-H]-@6.89	ME215221	0.74	1.26
PC 34:3; [M-Ac-H]-@5.82	ME215175	0.74	1.26
PE 34:2; [M-H]-@6.38	ME215190	0.74	1.26

Factors:

F1	Exercise:POST
F2	Exercise:PRE

Data matrix